Psoriasis Aggravated by Adalimumab: A Paradoxical Adverse Reaction.
- Author:
Ounjae PARK
1
;
Seung Gyun IN
;
Seong Min KANG
;
Seung Phil HONG
;
Hana BAK
;
Chong Hyun WON
;
Sung Eun CHANG
;
Mi Woo LEE
;
Jee Ho CHOI
;
Kee Chan MOON
Author Information
1. Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ppsion@naver.com
- Publication Type:Case Report
- Keywords:
Adalimumab;
Psoriasis;
Tumor necrosis factor
- MeSH:
Antibodies, Monoclonal, Humanized;
Arthritis;
Arthritis, Psoriatic;
Arthritis, Rheumatoid;
Biopsy;
Cyclosporine;
Female;
Humans;
Immunoglobulin G;
Inflammatory Bowel Diseases;
Middle Aged;
Psoriasis;
Skin;
Spondylarthritis;
Tumor Necrosis Factor-alpha;
Adalimumab
- From:Korean Journal of Dermatology
2010;48(6):513-516
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Adalimumab, a recombinant human IgG monoclonal antibody, selectively blocks tumor necrosis factor-alpha (TNF-alpha) and has been successfully used in the treatment of immune-mediated diseases. In particular, its efficacy has been proven in the treatment of rheumatoid arthritis, spondylarthritis, lymphoproliferative diseases and inflammatory bowel disease. Its use has also been studied for the treatment of psoriasis and yet, paradoxically, cases of new onset or exacerbation of psoriasis continue to increase in patients undergoing treatment with anti TNF-alpha agents. A 51-year-old woman had arthritis for a year and was diagnosed with psoriatic arthritis. After she had received adalimumab for psoriatic arthritis five times during one year, erythematous eruptions were found on her entire body. She then stopped adalimumab therapy for two months, although her skin lesions did not resolve. The patient was diagnosed with psoriasis through biopsy and began using cyclosporine, a topical steroid used for treatment of psoriasis.
